Coverage is a separate question from whether a drug has approval.
Medicare’s usual prescription-drug cover excludes medicines used only to lose weight, according to the rules as of September 26, 2026.
It may cover the same drug for another accepted medical use, depending on the plan.
A plan’s covered-drug list and any advance permission still matter.
The temporary Bridge program
Medicare also has a separate, temporary GLP-1 Bridge program. As of September 26, 2026, it offers certain weight-loss medicines for $50 for a month’s supply to people who qualify.
In the body, the hormone GLP-1 acts as a chemical messenger involved in blood sugar and appetite. The program covers certain medicines acting on that system.
The Bridge closes December 31, 2027 after opening on July 1, 2026; entry requires eligibility plus approval in advance.
- Covered products: semaglutide (Wegovy) injections or tablets; tirzepatide (Zepbound) only in the KwikPen injection pen; and orforglipron (Foundayo) tablets.
- You must be at least 18, have an eligible Medicare drug plan and meet weight and health rules.
- One route is a body mass index of at least 35. Body mass index is a number calculated from your height and weight. Lower numbers qualify only with specified health conditions.
- Type 2 diabetes keeps a person outside the Bridge because the usual Medicare drug-plan route applies to them.
- A Medicare drug plan’s payment in 2026 for any GLP-1 medicine makes you ineligible for the Bridge during 2026.
Other plan and health exclusions apply. Ask your prescriber to check the linked eligibility rules against your drug plan, weight and medical history.
Ask for confirmation of approval before budgeting for the $50 price.
Under the usual Medicare drug plan, your payments for covered medicines have an annual limit. Your $50 Bridge payments are additional costs and do not count toward that limit.